Burden of tuberculosis and challenges related to screening and diagnosis in Ethiopia.

AFB, acid fast bacilli ANC, ant-natal care ART, anti-retroviral therapy, DOTS, directly observed treatment, short course Diagnosis EPTB, extra pulmonary tuberculosis Ethiopia FMoH, Federal Ministry of Health HIV, human immunodeficiency virus MDR-TB, multi-drug resistant tuberculosis Maternal and child health NGOs, non-governmental organizations NTB, National TB program PFSA, Pharmaceutical Fund and Supply Agency PMTCT, prevention mother to child transmission PNC, postnatal care Screening TB, tuberculosis Tuberculosis WHO, World Health Organization Xpert mtb/rif assay eHMIS, electronic Health Management Information System

Journal

Journal of clinical tuberculosis and other mycobacterial diseases
ISSN: 2405-5794
Titre abrégé: J Clin Tuberc Other Mycobact Dis
Pays: England
ID NLM: 101682877

Informations de publication

Date de publication:
May 2020
Historique:
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 8 4 2020
Statut: epublish

Résumé

One-third of tuberculosis (TB) cases in Ethiopia are missing from care for reasons that are not well studied. The aim of this study was to assess TB burden and identify challenges related to TB screening and diagnosis in Ethiopia. A facility-based cross-sectional study was conducted in seven health facilities selected from two regions and 2 city administrations of Ethiopia using stratified random sampling procedures. The data of 1,059,065 patients were included from outpatient department, HIV clinic, diabetic, and maternal-child health clinics. Data were collected from October to December 2018 using a retrospective review of three years' facility data (2015 to 2017) supplemented by a semi-structured interview with purposively selected health care workers and heads of the health facilities. A total of 1,059,065 patients visited the health facilities in three years, of these, 978,480 (92.4%) were outpatients. Of the total, 20,284 (2%) were presumptive TB cases The burden of TB was high in the study setting, and frequent interruption of laboratory reagents and supplies hampered TB screening and diagnostic services. Realizing the END-TB strategy in such resource-limited settings requires sustainable TB diagnostic capacity and improved case detection mechanisms, with national TB programs strongly integrated into the general health care system.

Identifiants

pubmed: 32258437
doi: 10.1016/j.jctube.2020.100158
pii: S2405-5794(20)30016-4
pii: 100158
pmc: PMC7113623
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100158

Subventions

Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Organisme : Medical Research Council
ID : MR/M025470/1
Pays : United Kingdom

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

Authors declared that there are no conflicts of interest.

Références

Int J Tuberc Lung Dis. 2013 Nov;17(11):1396-401
pubmed: 24125440
J Infect Dis. 2017 Nov 6;216(suppl_7):S679-S685
pubmed: 29117350
J Educ Eval Health Prof. 2013 Nov 30;10:12
pubmed: 24324853
Glob Health Action. 2017;10(1):1290317
pubmed: 28598771
PLoS One. 2014 Jan 22;9(1):e85478
pubmed: 24465572
Lancet. 2010 May 22;375(9728):1814-29
pubmed: 20488524
Lancet Glob Health. 2018 Nov;6(11):e1196-e1252
pubmed: 30196093
BMC Health Serv Res. 2017 Mar 28;17(1):240
pubmed: 28351361
BMC Public Health. 2009 Aug 03;9:278
pubmed: 19646288
J Pregnancy. 2012;2012:565049
pubmed: 22007302
Tuberc Res Treat. 2019 Aug 21;2019:4578329
pubmed: 31531239
Tuberc Res Treat. 2016;2016:2036234
pubmed: 27066271
BMJ Glob Health. 2017 Nov 2;2(4):e000390
pubmed: 29209537
Biomed Res Int. 2017;2017:6325484
pubmed: 28904965
PLoS One. 2013 May 27;8(5):e63174
pubmed: 23723975
BMC Res Notes. 2014 Sep 10;7:629
pubmed: 25208473
J Clin Tuberc Other Mycobact Dis. 2017 Aug 12;9:1-4
pubmed: 31723710
Lancet. 2018 May 12;391(10133):1873-1875
pubmed: 29550031
Int J Tuberc Lung Dis. 2005 Nov;9(11):1183-203
pubmed: 16333924

Auteurs

Hussen Mohammed (H)

Department of Public Health, College of Medicine and Health Sciences, Dire Dawa University, Dire Dawa, Ethiopia.
Centre for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, P.O. Box 1362, Dire Dawa, Ethiopia.

Lemessa Oljira (L)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Kedir Teji Roba (KT)

School of Nursing and Midwifery, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Esther Ngadaya (E)

Muhimbili Research Centre, National Institute for Medical Research, Dares Saalem, Tanzania.

Tigest Ajeme (T)

Centre for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, P.O. Box 1362, Dire Dawa, Ethiopia.

Tewodros Haile (T)

Department of Internal Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Achenef Kidane (A)

Centre for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, P.O. Box 1362, Dire Dawa, Ethiopia.
Ohio State Global One Health initiative, Office of International Affairs, The Ohio State University, Addis Ababa, Ethiopia.

Tsegahun Manyazewal (T)

Centre for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, P.O. Box 1362, Dire Dawa, Ethiopia.

Abebaw Fekadu (A)

Centre for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, P.O. Box 1362, Dire Dawa, Ethiopia.
Global Health and Infection Department, Brighton and Sussex Medical School, Brighton, United Kingdom.

Getnet Yimer (G)

Centre for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, P.O. Box 1362, Dire Dawa, Ethiopia.
Ohio State Global One Health initiative, Office of International Affairs, The Ohio State University, Addis Ababa, Ethiopia.

Classifications MeSH